SEER INC
SEERNASDAQTrading Snapshot
- Day Range
- $2.12 – $2.16
- 52-Week Range
- $1.55 – $2.41
- Volume
- $1.78B
- Avg Volume
- $2.19B
- Shares Outstanding
- 55.0M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $16M
- Last Q Revenue
- $3M
- P/E Ratio
- -1.8
- P/S Ratio
- 8.5x
- EPS (TTM)
- $-1.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −6.1%
Why Investors Own SEER
- ✓High-growth profile — revenue up +35.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SEER INC
SEER
StockOtter · stockotter.spaceAbout SEER INC
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2
Seer Announces CFO Transition
REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Co
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, dise
Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.'s Board of Directors
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to director Meeta Guly
Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today issued the following open letter to the
Seer Q2 Earnings Call Highlights
Seer NASDAQ: SEER reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and g